Advise Saving Evenity for High-Risk Women With Osteoporosis

June 2019

Evenity (ee-VEN-ih-tee, romosozumab) is the first med to increase bone growth AND decrease bone breakdown for postmenopausal osteoporosis.

Other osteoporosis meds do one or the other. For example, Forteo (teriparatide) and Tymlos (abaloparatide) build bone. Bisphosphonates (alendronate, etc) and Prolia (denosumab) slow bone breakdown.

Evenity is the first "sclerostin inhibitor." It's an injectable monoclonal antibody that blocks this protein involved in bone metabolism.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
300+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Opioids Start a Dialogue About Tapering Chronic Opioids
Gastroenterology Don't Think of Meds as a Significant Source of Gluten
Diabetes Weigh Pros and Cons of SGLT2 Inhibitors for Kidney Protection
Cannabinoids Be Prepared for Patients to Ask About CBD
Menopause Clarify the Role of Bijuva for Vasomotor Symptoms
HIV & AIDS Expect to See Fewer Antibiotics for MAC Prophylaxis in Patients With HIV
Osteoporosis Advise Saving Evenity for High-Risk Women With Osteoporosis
Warts Tell Patients to Be Persistent When Treating Warts
Infectious Diseases Don't Advise Screening for UTIs in Most Patients Without Symptoms
Insomnia Explain Risk of Strange Sleep Behaviors With "Z-Drugs"

Advise Saving Evenity for High-Risk Women With Osteoporosis

Get concise advice on drug therapy, plus unlimited access to CE

Table of Contents